Stockscreener 앱 받기
10.05
7.20%
0.675
전일 마감가:
$9.375
열려 있는:
$9.45
하루 거래량:
33,799
Relative Volume:
0.23
시가총액:
$8.38M
수익:
-
순이익/손실:
$-14.93M
주가수익비율:
-0.0378
EPS:
-266.137
순현금흐름:
$-15.87M
1주 성능:
+11.67%
1개월 성능:
+47.36%
6개월 성능:
-89.29%
1년 성능:
-98.83%
1일 변동 폭
$9.1346
$10.30
1주일 범위
$8.28
$10.30
52주 변동 폭
$6.1478
$877.71
트랜스코드 테라 Stock (RNAZ) Company Profile
명칭
Transcode Therapeutics Inc
전화
857-301-6857
주소
6 LIBERTY SQUARE, BOSTON
RNAZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
10.05 | 7.50M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
트랜스코드 테라 주식(RNAZ)의 최신 뉴스
Will TransCode Therapeutics Inc. stock benefit from interest rate changesReal Time Stock Signal - Newser
What analysts say about CleanCore Solutions Inc. stock outlookSecure Your Capital Strategy - Newser
Is SS Innovations International Inc. stock a good hedge against inflationGroup Only Stock Signals - Newser
Why TransCode Therapeutics Inc. stock attracts strong analyst attentionSmart Money Trade Setups - Newser
RNAZ SEC FilingsTranscode Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What makes TransCode Therapeutics Inc. stock price move sharplyFree Group Entry - Newser
How TransCode Therapeutics Inc. stock performs during market volatilityFree Stock Market Entry & Exit Signals - Newser
When (RNAZ) Moves Investors should Listen - news.stocktradersdaily.com
TransCode Therapeutics (NASDAQ:RNAZ) Trading 14.9% Higher – Should You Buy? - Defense World
(RNAZ) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Head-To-Head Analysis: TransCode Therapeutics (NASDAQ:RNAZ) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Trading 4.7% Higher – Here’s Why - Defense World
TransCode Therapeutics Announces 2025 Annual Meeting Date - TipRanks
(RNAZ) Investment Analysis - news.stocktradersdaily.com
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
(RNAZ) On The My Stocks Page - news.stocktradersdaily.com
Transcode Therapeutics Appoints Dr. Phillip D. Zamore To Science Advisory Board - marketscreener.com
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - citybiz
TransCode Therapeutics appoints RNA expert to advisory board - Investing.com
TransCode Therapeutics appoints RNA expert to advisory board By Investing.com - Investing.com Nigeria
TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World
Certain Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announcement | RNAZ Stock News - GuruFocus
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World
Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday - Defense World
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
(RNAZ) Investment Report - news.stocktradersdaily.com
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan
TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga
TransCode Therapeutics announces reverse stock split - Medical Buyer
Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz
Is rnaz a good buy - AInvest
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com India
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus
Offerings News Live Feed - Stock Titan
Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com
TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com
TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus
TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com
TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan
트랜스코드 테라 (RNAZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.37%
자본화:
|
볼륨(24시간):